Biocon bags EU nod for pertuzumab biosimilar for HER2-positive breast cancer patients

By: IPP Bureau

Last updated : November 19, 2026 10:25 am



The approval covers the treatment of HER2-positive breast cancer across multiple disease stages in the European Union


Biocon has secured European Commission (EC) marketing authorisation for its pertuzumab biosimilar, Pebrilzo, marking a significant regulatory breakthrough as the first biosimilar approved under the European Medicines Agency’s (EMA) new tailored clinical approach.
 
The approval covers the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). It follows the biosimilar’s recent approval by the US Food and Drug Administration (FDA), further strengthening Biocon’s presence in the global oncology market.
 
The European approval also marks a major milestone for the Indian biopharmaceutical company, with pertuzumab becoming its fifth oncology biosimilar approved in both Europe and the United States.
 
Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. 
 
"With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”
 
Pebrilzo has been approved as a 420 mg concentrate for solution for infusion. Its active ingredient, pertuzumab, is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), helping inhibit the proliferation of tumour cells that overexpress the protein.
 
The biosimilar is indicated for use alongside trastuzumab and chemotherapy in the neoadjuvant treatment of adults with HER2-positive locally advanced, inflammatory or early-stage breast cancer who face a high risk of recurrence.
 
It is also approved for adjuvant treatment in adults with HER2-positive early breast cancer at high risk of recurrence.
 
For patients with metastatic or locally recurrent unresectable HER2-positive breast cancer, Pebrilzo can be used in combination with trastuzumab and docetaxel, provided they have not previously received anti-HER2 therapy or chemotherapy for their metastatic disease.
 
The approval is particularly significant as Pebrilzo is the first biosimilar to secure EC marketing authorisation under the EMA’s new tailored clinical approach. The European Commission's decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), issued on September 17, 2026.
 
Biocon said extensive structural and functional analytical characterisation, supported by comparative clinical pharmacokinetic data, established that its pertuzumab biosimilar is highly similar to the reference product.
 
According to the company, the studies demonstrated no clinically meaningful differences in quality, safety or efficacy.
 
The approval adds another key product to Biocon’s expanding oncology portfolio and strengthens its position in the biosimilars market, while potentially broadening access to biologic treatment options for patients with HER2-positive breast cancer across Europe.

Biocon European Commission marketing authorisation pertuzumab biosimilar Pebrilzo

First Published : November 19, 2026 12:00 am